HRTX
Heron Therapeuti
0.2942$
+1.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +79.8% | -51.0% | +247.2% | +97.3% | +10.9% | -31.1% | -13.5% | -17.9% | -11.3% | +4.8% | +9.7% | |
| – | +82.8% | -53.9% | +267.0% | +96.1% | +7.1% | -34.4% | -19.0% | -19.3% | -8.1% | +10.7% | +13.9% | |
| – | +3.4% | -82.2% | +977.9% | -78.0% | +125.8% | +46.2% | -13.9% | -83.0% | +86.7% | -10.0% | +11.0% | |
| – | +80.5% | -61.0% | +237.1% | +92.8% | +17.6% | -46.7% | -24.4% | -46.2% | -5.2% | -26.3% | -21.3% | |
| – | – | +4,255.6% | +2,036.4% | +54.4% | -38.3% | +4.9% | -15.2% | +46.6% | +15.5% | +31.2% | +13.6% | |
| – | – | – | +89.3% | +286.1% | -36.0% | +67.8% | +15.5% | +12.8% | -22.8% | +26.2% | +74.5% | |
| – | +8.1% | +66.5% | +17.8% | +145.4% | +33.7% | +15.9% | +47.6% | -11.2% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +44.9% | +349.6% | +16.3% | -10.8% | +18.4% | +7.5% | +94.9% | +4.1% | +8.0% | +4.0% | -9.5% | |
| – | +44.9% | +96.3% | +166.4% | -10.8% | +5.1% | +6.0% | -30.7% | +15.9% | -3.2% | +14.8% | +5.1% | |
| – | +39.0% | +31.0% | +885.4% | -84.1% | +65.1% | +33.1% | -76.0% | +11.5% | +14.1% | -1.2% | – | |
| – | +29.5% | +106.5% | +175.4% | -10.2% | -81.8% | -79.5% | +515.7% | -7.4% | +5.9% | +208.2% | -23.2% | |
| – | – | – | -100.0% | – | – | – | – | +0.1% | +16.4% | +0.6% | -19.5% | |
| – | +87.3% | -118.0% | – | +182.3% | +9.1% | -41.4% | -67.2% | -82.5% | -350.3% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +24.5% | +14.6% | +42.5% | +35.4% | +11.7% | +11.0% | +8.5% | +10.7% | +26.7% | +10.4% | +9.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.